Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
  • A61K47/544—Phospholipids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
  • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Definitions

• This invention relates to covalent conjugates of lipids and oligonucleotides and their use in the pharmaceutical, purification, and diagnostic arts.
• antisense RNA or DNA has proven useful for manipulating eukaryotic gene expression. This technique is based on blocking the informational flow from DNA to protein via RNA by introducing a complementary sequence to a portion of the target mRNA in the cell. When the oligomer is absorbed by the cells, it can either function in the cytoplasm by blocking translation of the target messenger or, upon penetrating the nucleus, interfere with nuclear processing or transcription by binding to DNA. In the case of viral infection, antisense oligomers may also function by blocking viral replication, depending on the target site of the oligomer on the viral genome. Complementary nucleic acids that inactivate gene expression have been designated antisense nucleic acids.
• Uptake of nucleotides by cells and liposomes is normally an inefficient process due to the high charge density of the nucleotide.
• a number of schemes have been used to improve incorporation efficiency, namely, calcium phosphate-mediated gene transfer (Chen, C.A. and Okayama, H., BioTechniques, 6:632 (1988)), use of retroviral vectors (Eglitis, M.A.et al., BioTechni ⁇ ues. 6: 608 (1988)), microinjection (DePamphilis, M.L.
• DNA covalently attached to cell receptor ligand proteins such as that for epidermal growth factor, was studied as a means to effect cell-specific DNA delivery.
• DNAs complexed with sugar-lysine conjugates Wang, G.Y. and Wu, C.H., J. Biol. Chem., 263: 14621 (1988)
• a positively charged lipid i.e., N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride, entrapped in a liposome
• a positively charged lipid i.e., N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride
• Protein-DNA conjugates are found in nature and are important in viral replication. Vartapetian and Bogdanov, A.A. Prog. Nucl. Acid Res. Mol. Biol., 34: 210 (1987).
• Non-natural hybrids have been prepared in which DNA is linked to targeting, cleaving, or reporter groups, including peptides, biotin, fluorescent dyes, and EDTA-Fe.
• Zuckermann et al. J. Am. Chem. Soc., 110: 6592 (1988); Haralambidis et al., Tetrahedron Lett.. 28: 5199 (1987); Connolly, Nucl. Acids Res.. 15: 3131 (1987); Agrawal et al., Nucl. Acids Res., 14: 6227 (1986); Smith et al., Nucl. Acids Res., H: 2399 (1985); Moser and Dervan, Science. 238: 645 (1987).
• Phosphatidyl nucleosides are biosynthetic intermediates in the lipid metabolism and a number of derivatives thereof showed interesting biological activities.
• U.S. Pat. No. 4,797,479 issued Jan. 10, 1989 to Shuto et al. phospholipid-nucleoside complex prepared by reacting L-glycerophospholipid with nucleoside in the presence of phospholipase D for treatment of tumors
• EP 273,085 published July 6, 1988, discloses linking a nucleic acid to a cell homing or targeting factor that promotes the penetration of the foreign nucleotides through the cell membrane, but has little specificity regarding cell recognition.
• targeting factors include low density lipoproteins, growth factors, viral antigens, and the B chain of toxins.
• the oligonucleotide has a nucleotide sequence sufficiently complementary to a pathogenic nucleic acid or an oncogene to hybridize thereto.
• the invention provides a conjugate that is labeled and one that is immobilized on a solid support.
• the invention provides a method for introducing the above conjugate into a host cell comprising transfecting the host cell with the conjugate.
• the invention supplies a composition comprising a pharmaceutically acceptable carrier and the conjugate, with the carrier preferably being a liposome.
• the invention provides a method comprising administering to a plant, animal, or human suffering from a pathogenic condition an effective amount of the above composition.
• the invention provides a method for the assay of a nucleic acid having a predetermined nucleotide sequence in a sample comprising:
• the invention provides a method for separating an oligonucleotide from a mixture, which method comprises:
• the invention provides a method for separating an oligonucleotide from a mixture, which method comprises:
• the invention provides a method for detecting lupus erythematosus in a human comprising contacting a serum sample from the human with a liposor ⁇ e comprising the conjugate and a label, said contacting being such that the antibodies bind to the oligonucleotide on the liposome, so as to alter the stability of the liposome; and measuring for the presence or absence of the label.
• the invention herein revolves around covalent conjugates of lipids and oligonucleotides that contain nucleotide sequences of interest or are sufficiently complementary to hybridize to sequences of interest.
• the lipid acts to internalize the nucleic acid sequence chemically coupled thereto into host cells, typically by endocytosis, and is bound to the oligonucleotide through a coupling sufficiently labile that it does not repress subsequent biochemical functioning of the oligonucleotide in the cell after internalization.
• the conjugate is a substrate for a cellular enzyme that cleaves the conjugate to release the oligonucleotide.
• the lipid is suitably covalently bonded to any moiety on the oligonucleotide, such as an amino group on the base, the hydroxyl group of the phosphate, or a hydroxyl group at the 5' or 3' terminus of the oligonucleotide. Preferably, however, it is bonded to the 5' hydroxyl group thereof.
• lipid refers to fats and fat-derived materials that are insoluble in water but soluble in biologically occurring hydrophobic solvents, related to fatty acid esters, fatty alcohols, sterols, or waxes, and utilizable by the animal organism.
• lipids include fatty acids and esters thereof, glycerides, e.g., triglycerides, glyceryl ethers, phospholipids, sphingolipids, fatty alcohols, waxes, terpenes, and steroids.
• Lipids include those that are derived naturally as well as those that are synthetically prepared.
• cleavage at the site will break the bond or hydrolyze the lipid so as to render the conjugate more water soluble.
• the cleavage site is susceptible to enzyme hydrolysis.
• the enzyme is located at a cellular or nuclear membrane or is in the cytoplasm of a cell.
• the most preferred lipids herein are phospholipids, where the enzyme that recognizes the cleavage site is a lipase, preferably a phospholipase.
• the cleavage site is the bond between the 5'-hydroxyloxygen atom of the oligonucleotide and the phosphorus atom (in the case of phospholipase D) or the bond between the oxygen atom on the glycerol side and the phosphorus atom (in the case of phospholipase C).
• Phospholipase C and D are ubiquitous membrane-bound cytoplasmic enzymes that catalyze the hydrolysis of certain phosphoester bonds, thereby cleaving the conjugate and releasing the oligonucleotide into the cytoplasm.
• Suitable phospholipids herein include, e.g., phosphoglycerides, plasmalogens, and other phosphatidic acids, sphingomyelin, and 3'-O-aminoacyl phosphatidyl glycerol.
• the "oligonucleotide” portion of the conjugate refers to a molecule comprised of two or more deoxyribonucleotides or ribonucleotides that has a nucleotide sequence that is either of interest or sufficiently complementary to hybridize to a nucleotide sequence of interest.
• the oligonucleotide is typically one that is capable of performing a biochemical function in receptor host cells and/or altering the operation of the cell machinery. Its exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. For example, if the oligonucleotide is to be used as an antisense oligomer, to ensure specificity thereof, the sequence must be unique in the mRNA population, and complementary to the target RNA.
• oligonucleotide contains at least five bases, more preferably, from about five to about thirty bases, and most preferably from about fourteen to about twenty-five bases.
• oligonucleotides herein are selected either to contain, or to be sufficiently complementary to hybridize to, the nucleotide sequence of interest. Therefore, the oligonucleotide sequence need not reflect the exact sequence of the nucleotide sequence of interest.
• a non-complementary nucleotide fragment may be attached to the 5' end of the oligonucleotide, with the remainder of the sequence being complementary to the nucleotide strand of interest.
• non-complementary bases or longer sequences can be interspersed into the oligonucleotide, provided that its sequence be capable of hybridizing to the target nucleic acid.
• oligonucleotide also includes oligonucleotides having modifications of the sugar-phosphodiester backbone to reduce their sensitivity to cellular nucleases and increase absorption by the cell as needed.
• oligonucleotides having modifications of the sugar-phosphodiester backbone to reduce their sensitivity to cellular nucleases and increase absorption by the cell as needed.
• One example is methylphosphonates wherein one of the oxygen atoms is substituted by a methyl group to result in four different substituents on the phosphorus atom, as disclosed by van der Krol et al., supra in Table 1.
• Oligomer methylphosphonates directed against HSV-1 immediate early mRNA-4 and -5 were found to prevent expression of herpetic lesions when applied in the form of cream to the HSV-infected ear of a mouse and were not toxic to mice when injected intravenously in concentrations up to 40 mg/kg body weight.
• phosphorothioates have been found to be potent inhibitors of viral proliferation, particularly HIV. Matsukura et al., Proc. Natl. Acad. Sci.. U.S.A., 84: 7706-7710 (1987); Agrawal et al., Proc. Natl. Acad. Sci. U.S.A., 85: 7079-7083 (1988).
• oligonucleotides also includes those with a covalently linked reagent besides the lipid that increases affinity for the complementary sequence. For example, coupling of poly-(L-lysine) to the 3' end of an antisense VSV oligonucleotide may be employed to enhance its antiviral activity. Further, a phosphorothioate oligomer may be coupled to a poly-(L-Iysine) to lower the effective dose. In addition, a phosphorothioate oligonucleotide is useful herein because it is stable to cleavage by nucleases, is very soluble in water, and hybridizes more efficiently with a complementary DNA sequence that the corresponding methylphosphonate analogs.
• An intercalating agent such as acridine may be added to the 3' end of the oligonucleotide to enhance its affinity for the target.
• Other methods include attaching to the antisense oligomer a reactive agent to modify the target nucleic acid irreversibly, including alkylating reagents, metal complexes such as EDTA-Fe(II), o-phenanthroline-Cu(I), or porphyrin-Fe(II).
• Such compounds generate hydroxyl radicals in the presence of molecular oxygen and a reducing agent and cleave the complementary strand following attack on the target nucleic acid backbone.
• a photocrosslinking agent can be attached to the oligomer, such as a psoralen derivative, azidophenacyl, and proflavine.
• the conjugate has the formula:
• Z is a C 2 -C 10 saturated or mono-, di- or polyunsaturated alkylene moiety, n, m, and y are independently an integer from 0 to about 10;
• A is selected from the group consisting of where B is a deprotected base, p is an integer from about 5 to 30, q and r are integers from about 1 to 28, provided that r + q is from about 4 to 29, s and t are integers from 0 to about 29, provided that s + 1 is from about 4 to 29, E is X or ZX, and D is selected from the group consisting of (where the bond from the ring nitrogens is attached to the sugar moiety of the oligonucleotide):
• alkyl and cycloalkyl refer to both straight-chain and branched alkyl groups and cycloalkyl groups with straight-chain or branched alkyl groups pending from the ring.
• "Mono-, di- and polyunsaturated” alkyl, cycloalkyl, or alkylene (divalent alkyl) moieties refer to hydrocarbons that contain one or more carbon-carbon double or triple bonds anywhere along their chain.
• Examples of compounds where L is an unsaturated cyclic or acyclic R 1 include terpenes, such as phytol, geraniol, limonene, farnesol, and squalene, vitamins, such as vitamins A, D, and K, and ß-carotene, and prostaglandins.
• L is a steroid moiety, preferably it is a sterol, and more preferably a sterol linked to the oligonucleotide through the hydroxyl group (either as an ether or ester) at its C 3 position.
• suitable steroids include cholesterol, lanosterol, a phytosterol, or a mycosterol such as, e.g., ergosterol.
• R 2 , R 3 , and R 4 may be combined to form an additional carbon to carbon bond.
• R 2 and R 3 are independently H or C 10 -C 20 saturated or unsaturated alkyl groups
• R 4 is H or R 1
• Y is O
• Z is ethylene or carboxyethylene
• n, m, and y are from 0 to 2, more preferably y is 1 or 2
• m is 1 or 2
• n is 0 or 1
• p is about 10 to 25
• q and r are from about 1 to 23, provided that their sum is from about 9 to 24, and s and t are from 0 to about 24, provided that their sum is from about 9 to 24.
• A is the oligonucleotide connected through its 5' end, more preferably where X is O. If A is connected off the N-base, it is preferably off the N6 of an adenine residue or the N4 of a cytosine residue. If R 2 , R 3 , and/or R 4 , preferably R 2 , is an ⁇ -amino acyl moiety, preferably H is derived from any amino acid, more preferably a naturally occurring amino acid, and most preferably lysine.
• At least one of the bases A in the formula above is a substantially planar base.
• the oligonucleotides so derivatized hybridize to their complementary RNA or DNA strand, the modified nucleoside remaining unpaired but nonetheless intercalated between adjacent base pairs in the duplex in a precisely stereochemically defined manner.
• the intercalating moiety is substituted with a reactive group capable of covalently modifying a predetermined site in the complementary domain.
• reactive groups include crosslinking agents and phosphate bond cleaving agents. These reactive groups are sterically confined and less likely to interact with cellular components or nucleic acid at sites other than the target complementary sequence.
• substantially planar in this context means that the steric bulk of the group lies substantially within an envelope approximating the steric gap bounded by the sugar backbone and flanking bases present in a complementary nucleic acid strand.
• this envelope has dimensions of about 30-50 Angstroms in width and depth and about 3-7 Angstroms in thickness.
• An example includes a nucleoside having the structure:
• R 3 is an aromatic polycycle
• Y is C or N
• R 1 and R 6 are H or a halogen, nitro, alkyl, hydroxyalkyl, or alkylether group wherein the alkyl group has 1 to 10 carbon atoms
• R 2 is a ribose or deoxyribose sugar.
• the nucleic acid sequences of interest include mRNA and DNA, and may be present in restriction enzyme digests or other fragments of nucleic acids, e.g., restriction fragment length polymorphisms (RFLPs).
• the nucleic acid or acids may be obtained from any source, for example, from plasmids such as pBR322, from cloned DNA or RNA, or from natural DNA or RNA from any source, including bacteria, yeast, viruses, and higher organisms such as plants or animals.
• the antisense oligonucleotides should be selected so as to have an efficient and specific interaction with the target mRNA, an efficient cellular uptake and compartmentalization of the oligonucleotide, and sufficient stability in the different cellular compartments.
• the oligonucleotide may contain a sequence that encodes a diagnostically useful protein, e.g., pathogenic proteins, such as those responsible for viral infections, including AIDS, oncogenes, growth factors, ß-globin, and the like.
• a diagnostically useful protein e.g., pathogenic proteins, such as those responsible for viral infections, including AIDS, oncogenes, growth factors, ß-globin, and the like.
• other nucleic acids that encode no protein may be of interest, e.g., transcription or translation control domains or sequences useful in forensic medicine.
• the conjugates herein have utility as agents for the antisense inhibition of translation of target nucleic acids.
• Such utilities have already been explored extensively with other antisense oligonucleotides (see van der Krol et al., supra, and WO 83/01451 published April 28, 1983), and the oligonucleotides herein will be used in substantially the same fashion, using a rational, specific design based on the sequence and secondary structure information of the target RNA or DNA, keeping in mind that the secondary or tertiary structures in the antisense RNA may influence the extent or rate of hybridization.
• the oligonucleotide has a nucleotide sequence capable of hybridizing to a pathogenic nucleic acid or an oncogene, more preferably viral or parasitic nucleic acid infecting a plant, such as a vegetable plant; animal, such as domestic, sports, and farm animals, e. g., dogs, cats, cows, and pigs; or human.
• antisense oligonucleotides can be used to inhibit viral infections of Rous sarcoma virus, vesicular stomatitis virus, type A influenza virus, herpes simplex virus, human immunodeficiency virus, and plant viruses such as potato virus X coat protein gene and cucumber mosaic virus coat protein gene, to inhibit parasitic, e.g., malarial, infections, and to reduce expression of proto-oncogene c-myc (for leukemia treatment), simian sarcoma virus, ß-globin, and ß-tubulin genes.
• Examples of published viral sequences that have inhibitory effects include those against Rous sarcoma virus (Zamecnik and Stephenson, Proc.
• oligonucleoside alkyl- or arylphosphonate analogues complementary to the target pathogenic sequence and including a functional group that reacts with the target nucleic acid to render it inactive or nonfunctional. These derivatives are described in EP 266,099 published May 4, 1988.
• the oligonucleotide has a nucleotide sequence representing, or capable of hybridizing to, a cleavage site specifically recognized by an enzyme endogenous to a host cell to which the conjugate is targeted.
• the oligonucleotide may encompass a sequence recognized by the RNase-H enzyme. This enzyme cleaves the RNA part of an RNA/DNA hybrid in vivo, resulting in subsequent degradation of the mRNA.
• the effect of the antisense oligomer can be catalytically enhanced by RNase-H activity.
• the invention herein includes antisense DNA or their analogs directed against splice-junction sites, especially when such antisense DNA has been found to be effective in inhibiting proliferation of HIV (Agrawal et al., Proc. Natl. Acad. Sci. U.S.A., 85: 7079-7083 (1988)), HSV (Smith et al., Proc. Natl. Acad. Sci.
• the invention is directed to complementary oligomers that are designed to interact with the cap site or the initiation codon region on the mRNA. Also, it has been shown that antisense oligomers blocking the ribosome attachment site are very effective for this purpose.
• the oligonucleotides herein are suitably prepared using conventional methods such as, for example, the phosphotriester or phosphodiester methods described by Narang, S.A. et al., Meth. Enzvmol.. 68: 90 (1979) and Brown, E.L.
• oligonucleotide that has been isolated from a biological source, such as a restriction endonuclease digest.
• the conjugates are prepared by any suitable technique.
• H-phosphonate methodology may be used to synthesize phospholipid conjugates, as described by Lindh and Stawinki, J. Nucleic Acids Res., Symp. Ser. No. 18, 189 (1987). Synthesis of the same compounds is also accomplished using phosphoramidite chemistry as described in Beaucage and Caruthers, Tetrahedron Lett., 1859 (1981) and McBride and Caruthers, Tetrahedron Lett., 245 (1983).
• the main advantage of using the H-phosphonate methodology is the flexibility in the oxidation procedure.
• DNA synthesis protocol can be employed for lipids that are normally stable to the deblocking conditions, i.e., concentrated ammonia.
• lipids include ether lipids or amide lipids, including triglycerides and sterols that contain amide functionalities in their backbone. Fatty acid derived lipids that contain ester linkages would not normally be stable to such conditions.
• the latter lipids can be conjugated by using the method of Chu et al., Nucl. Acids. Res.. 11: 6513-6529 (1983). This method requires that the lipid contain a free primary or secondary amino group.
• the lipid may already contain such an amino group in a side chain, as, e.g., in the case of phosphatidyl ethanolamine, phosphatidyl 3'-O-aminoacyl glycerol, and phosphatidyl serine, or it may be derivatized to contain such an amino group.
• the aminolipid is coupled to an oligomer- 5'-phosphate so as to produce lipid oligonucleotide conjugates.
• phospholipids may be suitably bonded to oligonucleotides enzymatically using phospholipase D, as has been reported for the synthesis of nucleoside lipid conjugates. See Shut o et al., supra.
• conjugate for the transfection of host cells so that DNA is stably incorporated therein.
• the transfection involves merely contacting the cells with the conjugate as by use of stirring at room temperature for at least about 15 hours, preferably about 20-30 hours.
• Another use is for the treatment of a mammal with a pathogenic condition that is alleviated or cured by use of an oligonucleotide with a nucleotide sequence that blocks a nucleic acid responsible for the condition.
• pathogenic condition that is alleviated or cured by use of an oligonucleotide with a nucleotide sequence that blocks a nucleic acid responsible for the condition.
• examples of such conditions include those caused by oncogenes and infections caused by viruses such as AIDS, herpes, hepatitis, etc.
• the mammal to be treated may be any mammalian species such as domestic and farm animals, including primates, and sports or pet animals, as well as humans.
• the preferred species being treated is human.
• the conjugate is administered to the patient by any suitable technique, including parenteral, sublingual, topical, intrapulmonary, and intranasal administration.
• parenteral sublingual, topical, intrapulmonary, and intranasal administration.
• the specific route of administration will depend, e.g., on the type of therapy required.
• parenteral administration include intramuscular, subcutaneous, intravenous, intraarterial, and intraperitoneal administration.
• the conjugates to be used in the therapy will be formulated and dosed in a fashion consistent with good medical practice taking into account the clinical condition of the individual patient, the cause of the condition in need of therapy, the site of delivery of the conjugate, the method of administration, the scheduling of administration, and other factors known to practitioners.
• the "effective amount" for purposes herein is thus determined by such considerations.
• the total pharmaceutically effective amount of the conjugate administered parenterally per dose will be in the range of about 1 ⁇ g/kg/day to 100 mg/kg/day of patient body weight, although, as noted above, this will be subject to a great deal of therapeutic discretion.
• the key factor in selecting an appropriate dose is the result obtained, as measured by elimination of infection or reduction in tumor or by other criteria as deemed appropriate by the practitioner.
• the conjugate is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, excipient, or stabilizer, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
• a pharmaceutically acceptable carrier i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
• Such materials include hydrophobic polymers, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins, sugar alcohols such as mannitol or sorbitol; and/or nonionic surfactants such as Tween, Pluronics, or PEG.
• the formulations are prepared by contacting the conjugates uniformly and intimately with liquid carriers, homogeneous phospholipid mixtures (for liposome encapsulation), or finely divided solid carriers, and then, if necessary, shaping the product into the desired formulation.
• the carrier is a parenteral carrier, more preferably a formulation that is isotonic with the blood of the recipient.
• the conjugate is prepared for storage or administration by mixing it, when it has the desired degree of purity, with physiologically acceptable carriers, excipients, or stabilizers. Such materials are non-toxic to recipients at the dosages and concentrations employed, and will depend on the water solubility of the conjugate. If the conjugate is water soluble, it may be formulated in a buffer such as phosphate or other organic acid salt preferably at a pH of about 7 to 8.
• the conjugate is not very soluble in water, it may be prepared as a microemulsion by formulating it with a nonionic surfactant such as Tween, Pluronics, or PEG, e.g., Tween 80, in an amount of 0.04-0.05% (w/v), to increase its solubility.
• a nonionic surfactant such as Tween, Pluronics, or PEG, e.g., Tween 80, in an amount of 0.04-0.05% (w/v), to increase its solubility.
• antioxidants e.g., ascorbic acid
• low molecular weight polypeptides e.g., polyarginine or tripeptides
• proteins such as serum albumin, gelatin, or immunoglobulins
• hydrophilic polymers such as polyvinylpyrrolidone
• amino acids such as glycine, glutamic acid, aspartic acid, or arginine
• monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, or dextrins
• chelating agents such as EDTA
• sugar alcohols such as mannitol or sorbitol.
• the conjugate to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). The conjugate ordinarily will be stored in lyophilized form or as an aqueous solution or emulsion.
• any reference to the conjugates herein also includes the pharmaceutically acceptable salts of such compounds, and it will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of such salts.
• pharmaceutically acceptable salts include those of alkaline earths (e.g., sodium or magnesium), ammonium or NX 4 + (wherein X is C 1-4 alkyl).
• Physiologically acceptable salts of a compound having a hydroxy group include the anion of said compound in combination with a suitable cation such as Na + , NH 4 + , and NX 4 + (wherein X is a C 1-4 alkyl group).
• Therapeutic conjugate compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
• sustained release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules.
• Sustained release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (U. Sidman et al., Biopolymers, 22, 547-556 (1983)), poly(2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res., 15: 167-277 (1981), and R. Langer, Chem. Tech., 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al., Id.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988).
• Sustained release conjugate formulations also include liposomally entrapped conjugates.
• Such systems have the advantage that biologically active material can be introduced into tissues by phagocytosis, especially into tissues of the reticuloendothelial system.
• Liposomes containing conjugates are prepared by methods known per se, including: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. U.S.A., 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. U.S.A., 77: 4030-4034 (1980); G. Gregoriadis, Liposome Technology. Vol. II.
• the liposome may be antibody-coated for increase in uptake by the cells, as taught by Wang and Huang, Proc. Natl. Acad. Sci. U.S.A., 84: 7851-7855 (1987).
• the liposomes obtained can be stored in the aqueous phase up to several weeks or months after addition of stabilizers, for example, lactose.
• the size of the liposomes formed depends, for example, on the structure of the active ingredient and the lipid component, the mixing ratio of the lipid components, and the concentration of these components in the aqueous dispersion. Thus, for example, by increasing or reducing the concentration of the lipid component it is possible to produce aqueous phases having a high content of small or large liposomes. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal therapy.
• the liposome-containing aqueous dispersion is suitably mixed with customary thickeners, for example, hydroxypropylcellulose, suitable preservatives, and antioxidants, and can be used in the form of a lotion or gel for application to the skin or mucous membranes.
• customary thickeners for example, hydroxypropylcellulose, suitable preservatives, and antioxidants
• the aqueous dispersion of the enriched liposomes can be suspended in a suitable carrier liquid, for example, sterile, calcium free, isotonic sodium chloride or glucose solution, optionally buffered to pH 7.2-7.4.
• the dose to be applied to a human of about 70 kg weight will range from about 200 mg to 1 g of liposomes containing about 0.1 to 500 mg of entrapped conjugate, respectively.
• the highest and lowest dose of the encapsulated material, the concentration of the phospholipids in the aqueous phase, as well as the proportions of the encapsulating phospholipids can be varied according to results to be established experimentally in clinical trials, the "effective amount" being thereby tied to the therapeutic results so obtained.
• the liposomal pharmaceutical administration system may consist of a kit of parts set comprising vials or bottles containing the phospholipids and conjugates.
• the conjugate therapy may be useful in conjunction with conventional chemotherapeutic agents, such as 5-fluorouracil. If the antisense oligomer is to be used for AIDS treatment, the conjugate therapy may be useful in conjunction with AZT, CD-4, and other experimental AIDS treatment agents.
• the conjugate herein is to be used for diagnostic purposes; it is labeled with a suitable label moiety, typically the oligonucleotide being labeled.
• suitable labels include radioactive labels such as 32 P, 125 I, 35 S, or the like, and non-radioactive labels such as, for example, biotin, thyroxine, enzymes such as hydrolases or peroxidases or phosphatases, and various chemiluminescers such as luciferin, or fluorescent compounds such as fluorescein and its derivatives.
• One diagnostic technique in which labeled conjugates are useful is in assays for nucleic acid having a predetermined nucleotide sequence in a sample relying on immobilization of the oligomeric probe on a solid support. Immobilizing the probe on a hydrophobic surface through the lipid moiety allows the oligonucleotide to be more accessible to hybridization than it is using, e.g., Southern blots or dot blots. Also, in the instant method, the filter need only be washed with a solution of the conjugate rather than heated to immobilize the nucleotides, as required for Southern blots.
• the method herein involves immobilizing the conjugate, in labeled form, on a support, preferably a solid matrix such as an agarose gel or a filter membrane, and contacting the sample with the immobilized conjugate such that the nucleic acid will hybridize with the oligonucleotide portion of the conjugate if the nucleic acid is present in the sample.
• a support preferably a solid matrix such as an agarose gel or a filter membrane
• Conditions for hybridization are well known and include those described in Maniatis, Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory, 1982).
• the support is washed to remove non-hybridizing materials and then the presence of labeled oligomers is determined.
• sample refers to any liquid or biological sample that contains or potentially contains the nucleic acid to be assayed.
• fluids such as human or animal body fluids, e.g., blood, serum, urine, amniotic fluid, tissue extracts, cerebrospinal fluid, and the like.
• the above diagnostic method is useful for detection of specific nucleic acid sequences associated with infectious diseases, genetic disorders, or cellular disorders such as cancer, e.g., oncogenes.
• Genetic diseases include specific deletions and/or mutations in genomic DNA from any organism, such as, e.g., sickle cell anemia, cystic fibrosis, ⁇ - thalassemia, ß-thalassemia, and the like.
• Infectious diseases can be diagnosed by the presence in clinic samples of specific DNA sequences characteristic of the causative microorganism. These include bacteria, such as Salmonella, Chlamydia, and Neisseria; viruses, such as the hepatitis viruses; and parasites, such as the Plasmodium responsible for malaria.
• a disease is characterized by the presence or absence of at least one specific restriction site in a specific nucleic acid sequence, such as sickle cell anemia and ß- thalassemia, it may be detected by the use of restriction enzymes.
• the immobilized conjugate is treated with a restriction endonuclease so as to cleave a restriction site within the oligonucleotide portion of the conjugate, producing labeled and unlabeled oligomer fragments, as described in U.S. Pat. No.4,725,537 issued February 16, 1988.
• the labeled oligomer fragments are then detected.
• DdeI [Geever et al., Proc. Natl.
• a liposome incorporating the conjugate, prepared as described above, and a label is used in the detection of lupus erythematosus in humans.
• the method involves contacting serum from the human patient with the liposome (where the conjugate acts as the lupus-specific antigen) under conditions such that if lupus autoantibodies are present (as are contained in patients with active lupus), they will bind to the oligonucleotide on the liposome, thereby either stabilizing or destabilizing the liposome; and measuring for the presence or absence of label. If the binding to the oligonucleotide destabilizes the liposome, the label will be released and the amount of label released is measured. If the binding stabilizes the liposome, the label is absent and will not be detected.
• the assay generally involves one-minute incubation of the serum at room temperature and can be performed with standard microtiter plates, allowing the screening of large numbers of sera, in a short time.
• the conditions employed for incubation are suitably those used in the colorimetric test for lupus described by Janof f et al., Clin. Chem. , 29: 1587-1592 (1983) and EP 90,735 published Oct. 5, 1983. These references describe the liposome stabilization embodiment.
• the oligonucleotide of the conjugate is double-stranded because it binds better to the antibodies. This may be accomplished by synthesizing a hairpin double-stranded nucleic acid, as is well known to those skilled in the art.
• conjugates herein is in the separation, isolation, or purification of a nucleic acid (e.g., oligonucleotides or polynucleotides) from a mixture of components.
• a nucleic acid e.g., oligonucleotides or polynucleotides
• This procedure takes advantage of the altered physical properties of the oligonucleotide on the conjugate because of the presence of the lipid.
• the conjugate employed is one that has a nucleotide sequence on the oligonucleotide that is substantially complementary to a sequence contained within the nucleic acid being purified.
• the lipid of the conjugate is used to immobilize the oligonucleotide on a solid support containing a hydrophobic surface such as plastic, silanized glass, alkyl sepharose or other hydrophobic interaction chromatography support, or an RP-HPLC matrix (e.g., alkyl silica gels such as C8 Vydec).
• a hydrophobic surface such as plastic, silanized glass, alkyl sepharose or other hydrophobic interaction chromatography support, or an RP-HPLC matrix (e.g., alkyl silica gels such as C8 Vydec).
• a buffer such as a phosphate buffer
• the lipid will adhere to the column under such aqueous conditions.
• the solid support is treated with the sample containing the complementary target nucleic acid, which hybridizes to the support under conditions that allow such hybridization as are well known to those skilled in the art. After hybridization the support is washed under different temperature or salt conditions than were employed to apply the
• the lipid portion of the conjugate is used for transporting the complementary target nucleic acid through a water-non-miscible phase.
• the conjugate having a nucleotide sequence capable of hybridizing to a sequence contained within the oligonucleotide to be separated, is provided in a hydrophobic phase, such as octanol, in a suitable vessel for extraction and transfer from an organic phase to an aqueous phase, such as a U-tube.
• the mixture containing the target nucleic acid is provided in a hydrophilic phase such as water in the vessel.
• the vessel also contains an aqueous phase without any nucleic acids, preferably pure water, into which the desired nucleic acid is transferred.
• the conjugate is partially soluble in both the aqueous and hydrophobic phases and its oligonucleotide portion would hybridize to the target strand, under suitable hybridizing conditions, and would then transport that strand through the hydrophobic phase into the pure hydrophilic phase. This procedure represents in effect a specific selective DNA extraction method.
• 1,2-di-O-hexadecyl-rac-glycerol (Sigma) in an amount of 342 mg (0.63 mmol) was evaporated from pyridine twice and then dissolved in 6 ml of pyridine and methylene chloride (1:1). After the flask was filled with argon, the solution, while being stirred at room temperature, was treated with van Boom's reagent (1.25 M solution in dioxane, 0.52 ml) (Marugg et al., Tetrahedron Lett.. 27: 2661 (1986)).
• the compounds prepared were: EL-T 10 ; EL-AGCTAGCT; EL-AGCTAGCTTTTTAGCTAGCT; EL-CAGTGATGTGT; EL- ACACATCACTG, in which EL represents 1,2-di-O-hexadecyl-3-glycerylphosphate bound to the 5' hydroxyl group of the DNA.
• EL-DNA samples were dissolved in formamide-containing buffer, heated to 90oC for one minute, and loaded on 15% acrylamide, 7 M urea gels. After running at 50 mA (approximately 400 V) for 2.5 hours, gels were photographed under uv illumination.
• the lipid-containing EL-DNAs (visualized by UV shadowing) were less mobile than the corresponding lipid-free DNAs and appeared as broad streaks surrounding a major band. In each case, this major band was approximately as mobile as a normal oligomer twice as long as the DNA of the EL-DNA.
• the different species were obtained as distinct, individual spots.
• the crude synthetic products typically showed two or three spots corresponding to EL-DNA, DNA, and sometimes a trace of unidentified material at lower Rf.
• the major material (UV and stain) in all cases was the high Rf (0.55-0.70) EL-DNA.
• the corresponding normal oligomers ran just above or just below the EL-DNAs.
• the relative locations of the compounds were constant, but their Rf values were variable.
• the color of the spots (produced by reaction with the molybdenum stain) differed.
• EL-DNA appeared purple, while DNA was dark blue (as was the unidentified minor spot).
• RP-HPLC was performed using a Waters Model 510 system and a 10 um C8 Partisil-10, 4.6 x 250 mm analytical column. RP-HPLC samples were loaded in 100% "A” buffer (25 mM aqueous triethylammonium phosphate (TEAP), pH 7.0, 5% CH 3 CN). Increasing amounts of "B" buffer (25 mM aqueous TEAP, pH 7.0, 75% CH 3 CN) were used to elute the samples from the column at a flow rate of 2.0 ml/min. Peaks were detected at 254 nm and were collected using an automated fraction collector.
• A aqueous triethylammonium phosphate
• B 25 mM aqueous TEAP, pH 7.0, 75% CH 3 CN
• EL-CAGTGATGTGT Further characterization of one EL-DNA (EL-CAGTGATGTGT) was carried out by enzymatic digestion.
• Snake venom phosphodiesterase (Boehringer Mannheim GmbH) catalyzed nearly complete hydrolysis of the DNA backbone (36°C, 30 min., 50 mM Tris, pH 8, 10 mM MgCl 2 ).
• Bovine spleen phosphodiesterase (Sigma), however, left the lipid-DNA intact (37°C, 1.5 hours, 50 mM Tris, pH 8, 10 mM MgCl 2 ).
• EL-CAGTGATGTGT was found to be incompetent as a substrate for both phospholipase C (Sigma, from Bacillus cereus) and phospholipase D (Sigma, from cabbage) under standard conditions (100 mM Tris, pH 8, 10 mM CaCl 2 , 36oC). RP-HPLC analysis of the digestion products showed only intact EL-DNA with each of the enzymes.
• Samples containing normal DNA (CAGTGATGTGT/ACACATCACTG), EL-DNA (EL-CAGTGATGTGT/EL-ACACATCACTG), or a mixture of DNA/EL-DNA (EL- CAGTGATGTGT/ ACACATCACTG and CAGTGATGTGT/EL-ACACATCACTG) in 1 ml of buffer (100 mM NaCl, 10 mM Na 2 HPO 4 , 1 mM EDTA, pH 7.2; each strand 2 ⁇ M) were placed in a masked 1-cm cuvette. All the samples were desalted (SEP-PAK C-18 minicolumn), HPLC-purified material. The insulated cell compartment was warmed from 10 to 80°C in 1°C increments with equilibration for 1 min. after attaining each temperature. UV absorbance at 260 nm was recorded automatically as a function of temperature.
• T m s for EL-CAGTGATGTGT/ACACATCACTG (38oC) and CAGTGATGTGT/EL-ACACATCACTG (33oC) were decreased relative to that of the normal duplex CAGTGATGTGT/ACACATCACTG (41°C).
• T m decreases for DNA-ligand conjugates See, for example, Kempe et al., Nucl. Acids Res., 13: 45 (1985).
• the varying degree of T m depression may simply reflect the differences in GC vs. AT content at the lipid-bearing end of each duplex.
• NIH/3T3 mouse fibroblasts can be transformed by ras oncogenes using calcium chloride transfection (see Graham and Van der Eb, Virology, 52: 456-467 (1973) and Wigler et al., Proc. Natl. Acad. Sci. U.S.A., 76: 1373-1376 (1979)).
• the transformed cells form foci of refringent cells that have lost contact inhibition and can grow in athymic mice.
• the human as oncogene (isolated from a plasmid, for example) is covalently coupled to a phospholipid by any of the techniques described above, including nitrogen linkage, or preferably is ligated to a lipid-oligonucleotide conjugate.
• a linker is constructed that is complementary to and spans the 3' end of the oligonucleotide of the conjugate to the 5' end of the human ras oncogene (which is contained in a linearized plasmid).
• This oligonucleotide portion of the conjugate, the linker, and the linearized plasmid are phosphorylated by standard kinase techniques and ligated together using T4 ligase.
• DMEM Dulbecco's Modified Eagle's medium
• DMEM Dulbecco's Modified Eagle's medium
• one of the lioid-ras conjugates is added to the medium and allowed to incubate for three hours at 37oC.
• Complete DMEM medium with 10% fetal calf serum is then added to the Petri dish, in an amount of 10:1 (v/v), and allowed to stand overnight at 37oC. The next day the cells are split in 1/20, 1/40, and 1/80 dilutions and left growing for 17 days, after which the foci are scored.
• the ras oncogene can be internalized into the cell, brought to the nucleus, and expressed to yield the ras oncogene product, showing that the conjugates can transform NIH/3T3 cells in a stable fashion.
• the present invention is directed to conjugates of oligonucleotides and lipids for transporting, targeting and internalizing the oligonucleotides to and within appropriate cells, generally by endocytosis.
• the conjugate is cleaved, for example, by cellular lipases that recognize an appropriate cleavage site on the conjugate.
• the conjugate herein suitably acts as a cytospecific drug capable of specific delivery to a cell of an oligomer expressing a polypeptide having various types of activities, for example, therapeutic, prophylactic, antiviral, cytotoxic, etc.
• the oligomer may affect the regulatory mechanism of the cell, complement a genetic defect, or serve as a marker.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Molecular Biology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Biochemistry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Biophysics (AREA)
• Virology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Dispersion Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Saccharide Compounds (AREA)
• Fats And Perfumes (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (2)

Family

ID=23245339

Family Applications (1)

Country Status (8)

Cited By (137)

Families Citing this family (3)

Citations (1)

• 1990
  • 1990-02-23 DK DK90904028.9T patent/DK0462145T3/da active
  • 1990-02-23 AT AT9090904028T patent/ATE104857T1/de not_active IP Right Cessation
  • 1990-02-23 ES ES90904028T patent/ES2055907T3/es not_active Expired - Lifetime
  • 1990-02-23 JP JP2504421A patent/JPH04503957A/ja active Pending
  • 1990-02-23 CA CA002049028A patent/CA2049028A1/en not_active Abandoned
  • 1990-02-23 WO PCT/US1990/001002 patent/WO1990010448A2/en active IP Right Grant
  • 1990-02-23 DE DE69008521T patent/DE69008521T2/de not_active Expired - Lifetime
  • 1990-02-23 EP EP90904028A patent/EP0462145B1/en not_active Expired - Lifetime

Patent Citations (1)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events